Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman

Blood (2024) 144 (Supplement 1): 4632.

https://doi.org/10.1182/blood-2024-198250

Published: 2024

Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Blood (2023) 142 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2023-180161

Published: 2023

Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D'Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman

Blood (2023) 142 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2023-174096

Published: 2023

Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 9269–9271.

https://doi.org/10.1182/blood-2022-167758

Published: 2022

Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2021-148544

Published: 2021

Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Blood (2021) 138 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2021-147460

Published: 2021

Journal Articles

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Mazyar Shadman, MD MPH, Jeff P Sharman, MD, Moshe Y. Levy, MD, Jamal Misleh, MD, Syed F. Zafar, MD, Benjamin B. Freeman, MD, John M. Burke, MD, Jennifer L. Cultrera, MD, Habte A. Yimer, MD, Dih-Yih Chen, MD, Xiaoping Zhang, MD, Aileen Cohen, MD PhD, Sunhee Ro, PhD, Jane Huang, MD, Ian W. Flinn, MD PhD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-134621

Published: 2020

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Eva Sahakian, Ph.D, Jennifer Rock-Klotz, B.S., Bijal D. Shah, MD, John Powers, B.S., Jennifer L. Cultrera, MD, Susan Deng, David M Woods, M.S., Michael Nguyen, Fengdong Cheng, MD, Hongwei Wang, Patricio Perez-Villarroel, B.S., Maritza Lienlaf, B.S., Tesa Knox, M.S., Selina Chen-Kiang, PhD, Alejandro Villagra, PhD, Jianguo Tao, MD, PhD, Javier Pinilla-Ibarz, MD, PhD, Simon S Jones, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 1660.

https://doi.org/10.1182/blood.V120.21.1660.1660

Published: 2012

Journal Articles

Primary CNS Lymphoma in a HIV Negative Population: A Review of Clinicopathologic Characteristics, Therapy, and Outcomes of 59 Patients

Michael V. Jaglal, MD, Bijal D. Shah, MD, Jennifer L. Cultrera, MD, Eduardo M. Sotomayor, MD, Michael B Tomblyn, MD, MS, Celeste M. Bello, MD, Lubomir Sokol, MD, PhD

Blood (2012) 120 (21): 4858.

https://doi.org/10.1182/blood.V120.21.4858.4858

Published: 2012

Journal Articles

Double and Triple Hit Diffuse Large B Cell Lymphomas and First Line Therapy

Michael V. Jaglal, MD, Deniz Peker, MD, Jianguo Tao, MD, PhD, Jennifer L. Cultrera, MD

Blood (2012) 120 (21): 4885.

https://doi.org/10.1182/blood.V120.21.4885.4885

Published: 2012

Journal Articles

Time to Treatment of Greater Than 1 Year Optimally Stratifies Patients with Improved Survival in Mantle Cell Lymphoma

Bijal D. Shah, MD, Peter Martin, MD, Jennifer L. Cultrera, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD

Blood (2012) 120 (21): 5082.

https://doi.org/10.1182/blood.V120.21.5082.5082

Published: 2012

Journal Articles

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Jolly R Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Melissa L. Teichman, PharmD, BCOP, Lubomir Sokol, MD, PhD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Eduardo M. Sotomayor, Gene A. Wetzstein, PharmD, BCOP

Blood (2011) 118 (21): 4973.

https://doi.org/10.1182/blood.V118.21.4973.4973

Published: 2011

Journal Articles

Hypercvad for Treatment of Adult Acute Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Kendra L. Sweet, MD, Robert M. Crescentini, II, MD, Jennifer L. Cultrera, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD

Blood (2011) 118 (21): 4241.

https://doi.org/10.1182/blood.V118.21.4241.4241

Published: 2011

Journal Articles

Outcomes and Prognostic Factors in Adolescents and Young Adults Undergoing Intensive Therapy for Acute Lymphoblastic Leukemia

Kendra L. Sweet, MD, Robert M. Crescentini, II, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jennifer L. Cultrera, MD

Blood (2011) 118 (21): 4248.

https://doi.org/10.1182/blood.V118.21.4248.4248

Published: 2011

Journal Articles

Treating Acute Lymphocytic Leukemia in the Older Adult: the Moffitt Cancer Center Experience

Robert M. Crescentini,, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jennifer L. Cultrera, MD

Blood (2011) 118 (21): 4229.

https://doi.org/10.1182/blood.V118.21.4229.4229

Published: 2011

Journal Articles

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Heather Barnes Pound, PharmD, BCPS, Viet Q. Ho, PharmD, BCOP, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Martine Extermann, MD, PhD, Jeffrey E. Lancet, MD, Eduardo M. Sotomayor, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 4620.

https://doi.org/10.1182/blood.V118.21.4620.4620

Published: 2011

Journal Articles

A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas

Jennifer L. Cultrera, MD, Jijun Liu, MD, Idalia Liboy, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, PhD, Eduardo M. Sotomayor, MD, Enrique Santana, RN, Fernando Cabanillas, MD

Blood (2010) 116 (21): 2879.

https://doi.org/10.1182/blood.V116.21.2879.2879

Published: 2010

Journal Articles

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Rebecca Tombleson, Viet Q. Ho, PharmD, BCOP, Eduardo M. Sotomayor, MD, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Javier Pinilla-Ibarz, MD, Lubomir Sokol, MD, PhD, Gene A. Wetzstein, PharmD, BCOP

Blood (2010) 116 (21): 4370.

https://doi.org/10.1182/blood.V116.21.4370.4370

Published: 2010

Journal Articles

Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) as An Indicator of Overall Survival, Progression Free Survival, Survival From Relapse

Bijal D. Shah, MD, Jennifer L. Cultrera, MD, Lubomir Sokol, MD, PhD, Paul A. Chervenick, MD, Celeste M. Bello, MD, Elizabeth M. Sagatys, MD, Lynn C. Moscinski, MD, Ling Zhang, MD, Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD

Blood (2010) 116 (21): 5082.

https://doi.org/10.1182/blood.V116.21.5082.5082

Published: 2010

NARROW

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Primary CNS Lymphoma in a HIV Negative Population: A Review of Clinicopathologic Characteristics, Therapy, and Outcomes of 59 Patients

Double and Triple Hit Diffuse Large B Cell Lymphomas and First Line Therapy

Time to Treatment of Greater Than 1 Year Optimally Stratifies Patients with Improved Survival in Mantle Cell Lymphoma

Rapid Infusion Rituximab in Maintenance Therapy: Is It Feasible?

Hypercvad for Treatment of Adult Acute Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Outcomes and Prognostic Factors in Adolescents and Young Adults Undergoing Intensive Therapy for Acute Lymphoblastic Leukemia

Treating Acute Lymphocytic Leukemia in the Older Adult: the Moffitt Cancer Center Experience

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas

Optimizing Premedications In the Prevention of Bendamustine Infusion Related Reactions

Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) as An Indicator of Overall Survival, Progression Free Survival, Survival From Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only